ID   MM96L
AC   CVCL_D853
SY   96L; MM96 Late passage
DR   cancercelllines; CVCL_D853
DR   ChEMBL-Cells; CHEMBL3307555
DR   ChEMBL-Targets; CHEMBL614170
DR   Cosmic; 889038
DR   Cosmic; 1028798
DR   Cosmic; 2013935
DR   GEO; GSM170979
DR   GEO; GSM228385
DR   Progenetix; CVCL_D853
DR   PubChem_Cell_line; CVCL_D853
DR   Wikidata; Q54906197
RX   PubMed=1422191;
RX   PubMed=2798324;
RX   PubMed=3127479;
RX   PubMed=9466661;
RX   PubMed=15048078;
RX   PubMed=17516929;
CC   Doubling time: 22.0 hours (PubMed=2798324).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D848 ! MM96
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 24
//
RX   PubMed=1422191; DOI=10.1097/00008390-199201000-00007;
RA   Takahashi H., Schumann R., Quinn R.J., Briscoe T.A., Parsons P.G.;
RT   "Isomers of a marine diterpene distinguish sublines of human melanoma
RT   cells on the basis of apoptosis, cell cycle arrest and differentiation
RT   markers.";
RL   Melanoma Res. 1:359-366(1992).
//
RX   PubMed=2798324; DOI=10.1111/j.1600-0749.1989.tb00211.x;
RA   Brown J.K., Mountford M.H., Allen B.J., Mishima Y., Ichihashi M.,
RA   Parsons P.G.;
RT   "Neutron irradiation of human melanoma cells.";
RL   Pigment Cell Res. 2:319-324(1989).
//
RX   PubMed=3127479; DOI=10.1111/1523-1747.ep12461022;
RA   McEwan M., Parsons P.G., Moss D.J.;
RT   "Monoclonal antibody against human tyrosinase and reactive with
RT   melanotic and amelanotic melanoma cells.";
RL   J. Invest. Dermatol. 90:515-519(1988).
//
RX   PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D;
RA   White C.A., Thomson S.A., Cooper L.T., van Endert P.M., Tampe R.,
RA   Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.;
RT   "Constitutive transduction of peptide transporter and HLA genes
RT   restores antigen processing function and cytotoxic T cell-mediated
RT   immune recognition of human melanoma cells.";
RL   Int. J. Cancer 75:590-595(1998).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//